|
1
|
Cappuzzo F, Gregorc V, Rossi E, et al:
Gefitinib in pretreated non-small-cell lung cancer (NSCLC):
Analysis of efficacy and correlation with HER2 and epidermal growth
factor receptor expression in locally advanced or metastatic NSCLC.
J Clin Oncol. 21:2658–2663. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cappuzzo F, Hirsch FR, Rossi E, et al:
Epidermal growth factor receptor gene and protein and gefitinib
sensitivity in non-small-cell lung cancer. J Natl Cancer Inst.
97:643–655. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Paez JG, Janne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pao W and Miller VA: Epidermal growth
factor receptor mutations, small-molecule kinase inhibitors, and
non-small-cell lung cancer: current knowledge and future
directions. J Clin Oncol. 23:2556–2568. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kosaka T, Yatabe Y, Endoh H, Kuwano H,
Takahashi T and Mitsudomi T: Mutations of the epidermal growth
factor receptor gene in lung cancer: biological and clinical
implications. Cancer Res. 64:8919–8923. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Slebos RJ, Hruban RH, Dalesio O, Mooi WJ,
Offerhaus GJ and Rodenhuis S: Relationship between K-ras oncogene
activation and smoking in adenocarcinoma of the human lung. J Natl
Cancer Inst. 83:1024–1027. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tsao MS, Aviel-Ronen S, Ding K, et al:
Prognostic and predictive importance of p53 and RAS for adjuvant
chemotherapy in non small-cell lung cancer. J Clin Oncol.
25:5240–5247. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eberhard DA, Johnson BE, Amler LC, et al:
Mutations in the epidermal growth factor receptor and in KRAS are
predictive and prognostic indicators in patients with
non-small-cell lung cancer treated with chemotherapy alone and in
combination with erlotinib. J Clin Oncol. 23:5900–5909. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Febbo PG, Ladanyi M, Aldape KD, et al:
NCCN Task Force report: Evaluating the clinical utility of tumor
markers in oncology. J Natl Compr Canc Netw. 9 (Suppl 5):S1–S32.
2011.
|
|
11
|
Sequist LV, Heist RS, Shaw AT, et al:
Implementing multiplexed genotyping of non-small-cell lung cancers
into routine clinical practice. Ann Oncol. 22:2616–2624. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Janne PA, Shaw AT, Pereira JR, et al:
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell
lung cancer: a randomised, multicentre, placebo-controlled, phase 2
study. Lancet Oncol. 14:38–47. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shin HR, Masuyer E, Ferlay J and Curado
MP: Asian Contributors to CI5 IX4: Cancer in Asia - Incidence rates
based on data in cancer incidence in five continents IX
(1998–2002). Asian Pac J Cancer Prev. 11 (Suppl 2):11–16.
2010.PubMed/NCBI
|
|
14
|
Alberg AJ, Ford JG and Samet JM: American
College of Chest Physicians: Epidemiology of lung cancer: ACCP
evidence-based clinical practice guidelines (2nd edition). Chest.
132 (Suppl 3):29S–55S. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ainbinder DJ, Esmaeli B, Groo SC, Finger
PT and Brooks JP: Introduction of the 7th edition eyelid carcinoma
classification system from the American Joint Committee on
Cancer-International Union Against Cancer staging manual. Arch
Pathol Lab Med. 133:1256–1261. 2009.PubMed/NCBI
|
|
16
|
Beasley MB, Brambilla E and Travis WD: The
2004 World Health Organization classification of lung tumors. Semin
Roentgenol. 40:90–97. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Travis WD, Brambilla E, Noguchi M, et al:
International Association for the Study of Lung Cancer/American
Thoracic Society/European Respiratory Society international
multidisciplinary classification of lung adenocarcinoma. J Thorac
Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takano T, Ohe Y, Sakamoto H, et al:
Epidermal growth factor receptor gene mutations and increased copy
numbers predict gefitinib sensitivity in patients with recurrent
non-small-cell lung cancer. J Clin Oncol. 23:6829–6837. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Carney DN: Lung cancer - time to move on
from chemotherapy. N Engl J Med. 346:126–128. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chute JP, Chen T, Feigal E, Simon R and
Johnson BE: Twenty years of phase III trials for patients with
extensive-stage small-cell lung cancer: perceptible progress. J
Clin Oncol. 17:1794–1801. 1999.PubMed/NCBI
|
|
21
|
Henschke CI, McCauley DI, Yankelevitz DF,
et al: Early lung cancer action project: Overall design and
findings from baseline screening. Lancet. 354:99–105. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Henschke CI, Naidich DP, Yankelevitz DF,
et al: Early lung cancer action project: Initial findings on repeat
screenings. Cancer. 92:153–159. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kaneko M, Kusumoto M, Kobayashi T, et al:
Computed tomography screening for lung carcinoma in Japan. Cancer.
89 (Suppl):2485–2488. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
National Comprehensive Cancer Network,
Inc. (NCCN), . Lung Cancer Screening. Version 1. 2012, NCCN; Fort
Washington, USA: 2011, http://www.lungcanceralliance.org/assets/docs/news/NCCN%20Screening%20Guidelines%2010_11.pdf
|
|
25
|
Takashima S, Maruyama Y, Hasegawa M, et
al: CT findings and progression of small peripheral lung neoplasms
having a replacement growth pattern. AJR Am J Roentgenol.
180:817–826. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kuriyama K, Seto M, Kasugai T, et al:
Ground-glass opacity on thin-section CT: value in differentiating
subtypes of adenocarcinoma of the lung. AJR Am J Roentgenol.
173:465–469. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Aoki T, Tomoda Y, Watanabe H, et al:
Peripheral lung adenocarcinoma: correlation of thin-section CT
findings with histologic prognostic factors and survival.
Radiology. 220:803–809. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kodama K, Higashiyama M, Yokouchi H, et
al: Prognostic value of ground-glass opacity found in small lung
adenocarcinoma on high-resolution CT scanning. Lung Cancer.
33:17–25. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Carneiro JG, Couto PG, Bastos-Rodrigues L,
et al: Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and
TTF-1 expression in Brazilian lung cancer patients. Genet Res
(Camb). 96:e0022014.PubMed/NCBI
|
|
30
|
Das BR, Bhaumik S, Ahmad F, et al:
Molecular spectrum of somatic EGFR and KRAS gene mutations in non
small cell lung carcinoma: Determination of frequency, distribution
pattern and identification of novel variations in Indian patients.
Pathol Oncol Res. Jan 31–2015.(Epub ahead of print). View Article : Google Scholar
|
|
31
|
National Comprehensive Cancer Network,
Inc. (NCCN), . Non-Small Cell Lung Cancer. Version 2. 2013, NCCN;
Fort Washington, USA: 2013, http://www.tri-kobe.org/nccn/guideline/lung/english/non_small.pdf
|
|
32
|
Cappuzzo F, Finocchiaro G, Metro G, et al:
Clinical experience with gefitinib: an update. Crit Rev Oncol
Hematol. 58:31–45. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sequist LV, Joshi VA, Janne PA, et al:
Response to treatment and survival of patients with non-small cell
lung cancer undergoing somatic EGFR mutation testing. Oncologist.
12:90–98. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ji H, Li D, Chen L, et al: The impact of
human EGFR kinase domain mutations on lung tumorigenesis and in
vivo sensitivity to EGFR-targeted therapies. Cancer Cell.
9:485–495. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lund-Iversen M, Kleinberg L,
Fjellbirkeland L, Helland A and Brustugun OT: Clinicopathological
characteristics of 11 NSCLC patients with EGFR-exon 20 mutations. J
Thorac Oncol. 7:1471–1473. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yasuda H, Kobayashi S and Costa DB: EGFR
exon 20 insertion mutations in non-small-cell lung cancer:
preclinical data and clinical implications. Lancet Oncol.
13:e23–e31. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shi Y, Au JS, Thongprasert S, et al: A
prospective, molecular epidemiology study of EGFR mutations in
Asian patients with advanced non-small-cell lung cancer of
adenocarcinoma histology (PIONEER). J Thorac Oncol. 9:154–162.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Riely GJ, Pao W, Pham D, et al: Clinical
course of patients with non-small cell lung cancer and epidermal
growth factor receptor exon 19 and exon 21 mutations treated with
gefitinib or erlotinib. Clin Cancer Res. 12:839–844. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sun JM, Won YW, Kim ST, et al: The
different efficacy of gefitinib or erlotinib according to epidermal
growth factor receptor exon 19 and exon 21 mutations in Korean
non-small cell lung cancer patients. J Cancer Res Clin Oncol.
137:687–694. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tam IY, Chung LP, Suen WS, et al: Distinct
epidermal growth factor receptor and KRAS mutation patterns in
non-small cell lung cancer patients with different tobacco exposure
and clinicopathologic features. Clin Cancer Res. 12:1647–1653.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Marks JL, Broderick S, Zhou Q, et al:
Prognostic and therapeutic implications of EGFR and KRAS mutations
in resected lung adenocarcinoma. J Thorac Oncol. 3:111–116. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yano M, Sasaki H, Kobayashi Y, et al:
Epidermal growth factor receptor gene mutation and computed
tomographic findings in peripheral pulmonary adenocarcinoma. J
Thorac Oncol. 1:413–416. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yoshida Y, Kokubu A, Suzuki K, et al:
Molecular markers and changes of computed tomography appearance in
lung adenocarcinoma with ground-glass opacity. Jpn J Clin Oncol.
37:907–912. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chung JH, Choe G, Jheon S, et al:
Epidermal growth factor receptor mutation and pathologic-radiologic
correlation between multiple lung nodules with ground-glass opacity
differentiates multicentric origin from intrapulmonary spread. J
Thorac Oncol. 4:1490–1495. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Glynn C, Zakowski MF and Ginsberg MS: Are
there imaging characteristics associated with epidermal growth
factor receptor and KRAS mutations in patients with adenocarcinoma
of the lung with bronchioloalveolar features? J Thorac Oncol.
5:344–348. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Park EA, Lee HJ, Kim YT, et al: EGFR gene
copy number in adenocarcinoma of the lung by FISH analysis:
investigation of significantly related factors on CT, FDG-PET, and
histopathology. Lung Cancer. 64:179–186. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lee Y, Lee HJ, Kim YT, et al: Imaging
characteristics of stage I non-small cell lung cancer on CT and
FDG-PET: relationship with epidermal growth factor receptor protein
expression status and survival. Korean J Radiol. 14:375–383. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hsu KH, Chen KC, Yang TY, et al: Epidermal
growth factor receptor mutation status in stage I lung
adenocarcinoma with different image patterns. J Thorac Oncol.
6:1066–1072. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Aoki T, Hanamiya M, Uramoto H, Hisaoka M,
Yamashita Y and Korogi Y: Adenocarcinomas with predominant
ground-glass opacity: correlation of morphology and molecular
biomarkers. Radiology. 264:590–596. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Riely GJ, Politi KA, Miller VA and Pao W:
Update on epidermal growth factor receptor mutations in non-small
cell lung cancer. Clin Cancer Res. 12:7232–7241. 2006. View Article : Google Scholar : PubMed/NCBI
|
